Jpmorgan Chase & CO Arrowhead Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2,148,405 shares of ARWR stock, worth $42.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,148,405
Previous 2,315,705 7.22%
Holding current value
$42.2 Million
Previous $60.2 Million 30.89%
% of portfolio
0.0%
Previous 0.01%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Dec 26, 2024
SELL
$19.36 - $29.54 $3.24 Million - $4.94 Million
-167,300 Reduced 7.22%
2,148,405 $41.6 Million
Q3 2024

Nov 08, 2024
SELL
$19.36 - $29.54 $3.24 Million - $4.94 Million
-167,300 Reduced 7.22%
2,148,405 $41.6 Million
Q2 2024

Dec 26, 2024
BUY
$21.87 - $28.24 $3.66 Million - $4.72 Million
167,300 Added 7.79%
2,315,705 $60.2 Million
Q2 2024

Aug 12, 2024
SELL
$21.87 - $28.24 $7.05 Million - $9.1 Million
-322,358 Reduced 12.22%
2,315,705 $60.2 Million
Q1 2024

Dec 26, 2024
BUY
$27.21 - $39.48 $13.3 Million - $19.3 Million
489,658 Added 22.79%
2,638,063 $75.4 Million
Q1 2024

May 10, 2024
SELL
$27.21 - $39.48 $3.07 Million - $4.46 Million
-112,985 Reduced 4.11%
2,638,063 $75.4 Million
Q4 2023

Dec 26, 2024
BUY
$21.2 - $31.03 $12.8 Million - $18.7 Million
602,643 Added 28.05%
2,751,048 $84.2 Million
Q4 2023

Feb 12, 2024
SELL
$21.2 - $31.03 $679,460 - $994,511
-32,050 Reduced 1.15%
2,751,048 $84.2 Million
Q3 2023

Nov 14, 2023
SELL
$26.2 - $36.08 $2.56 Million - $3.53 Million
-97,816 Reduced 3.4%
2,783,098 $74.8 Million
Q2 2023

Aug 11, 2023
SELL
$25.16 - $41.38 $730,923 - $1.2 Million
-29,051 Reduced 1.0%
2,880,914 $103 Million
Q1 2023

May 18, 2023
BUY
$23.68 - $38.51 $6.28 Million - $10.2 Million
265,031 Added 10.02%
2,909,965 $73.9 Million
Q1 2023

May 11, 2023
SELL
$23.68 - $38.51 $4.17 Million - $6.77 Million
-175,888 Reduced 6.24%
2,644,934 $67.2 Million
Q4 2022

Feb 13, 2023
SELL
$28.0 - $40.56 $2.01 Million - $2.91 Million
-71,699 Reduced 2.48%
2,820,822 $114 Million
Q3 2022

Nov 14, 2022
SELL
$29.63 - $48.31 $2.91 Million - $4.75 Million
-98,294 Reduced 3.29%
2,892,521 $95.6 Million
Q2 2022

Aug 11, 2022
BUY
$27.79 - $50.61 $1.94 Million - $3.54 Million
69,862 Added 2.39%
2,990,815 $105 Million
Q1 2022

May 11, 2022
SELL
$39.62 - $69.97 $2.3 Million - $4.07 Million
-58,111 Reduced 1.95%
2,920,953 $134 Million
Q4 2021

Feb 10, 2022
BUY
$58.09 - $82.51 $8.12 Million - $11.5 Million
139,822 Added 4.92%
2,979,064 $198 Million
Q3 2021

Nov 12, 2021
BUY
$58.38 - $84.96 $166 Million - $241 Million
2,839,242 New
2,839,242 $177 Million

Others Institutions Holding ARWR

# of Institutions
294
Shares Held
90.8M
Call Options Held
155K
Put Options Held
426K
View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

ARWR Quotes by TradingView
  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.08B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email